← Natural Eye Care

Macular degeneration: what it is, and what the research shows

By Dr. Glen Swartwout, Naturopathic Optometrist

I am retired from licensed practice, and I now write and teach about natural eye care.

This page is education, not a diagnosis or a treatment plan.

Macular degeneration damages the macula, the part of the retina used for reading and faces.

Side vision usually stays.

One review calls it "the leading cause of severe and irreversible vision loss in the Western world."

Source: Smoking and age-related macular degeneration: a review of association

A 2014 review estimated it affected 196 million people by 2020, "increasing to 288 million in 2040."

Source: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

Early, dry and wet

Early and intermediate stages show drusen, the yellow deposits under the retina.

My page on drusen explains what they are, and what the research shows about their change over time.

The late stage takes one of two forms.

Late dry disease is called geographic atrophy.

Patches of retina slowly waste away.

In wet disease, new blood vessels grow under the retina and leak.

Source: Clinical classification of age-related macular degeneration

Wet disease can harm sight quickly.

Sudden blurring or wavy lines need an eye doctor within days.

Who is at risk

Age is the largest risk factor.

Genes matter too.

One large study found 52 gene variants linked with the disease, across 34 regions of the genome.

Source: A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants

Smoking is the largest risk you can change.

One review of 17 studies found "increased risk of AMD of two- to three-fold in current-smokers."

Five of those studies found no link.

Source: Smoking and age-related macular degeneration: a review of association

In another study, risk rose with the number of years smoked.

There, "the risk in those who had not smoked for over 20 years was comparable to non-smokers."

That study also linked passive smoking with higher risk.

Source: Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation

These smoking studies observed people.

None was a trial.

What food studies show

One study followed about 100000 people for two decades.

People with the highest predicted blood levels of lutein and zeaxanthin had about 40% less advanced disease.

The study found no link with intermediate disease.

Source: Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up

Lutein and zeaxanthin are found in leafy greens such as kale and spinach, and in egg yolk.

Eating fish at least twice a week was linked with less late disease.

The same review found "insufficient evidence" to recommend fish for prevention.

Source: Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis

Studies like these show links.

They cannot prove that the food caused the difference.

The large supplement trials

The first large trial included 3640 people.

It tested antioxidants and zinc, alone or together.

The antioxidants were vitamin C, vitamin E and beta carotene.

Copper was added alongside the zinc.

The full combination lowered the odds of advanced disease, with an odds ratio of 0.72.

That is roughly a quarter lower.

The benefit was in people at higher risk, not in those with early disease.

People with early changes had "only a 1.3% 5-year probability of progression to advanced AMD."

Source: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

The second trial included 4203 people.

It added lutein and zeaxanthin or omega-3 oils to the first formula.

Its main result: "no statistically significant reduction in progression to advanced AMD."

Source: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial

Over ten years, lutein and zeaxanthin in place of beta carotene was linked with somewhat less late disease.

The same follow-up found "Beta carotene usage nearly doubled the risk of lung cancer."

The extra lung cancers were mostly in former smokers.

So smokers and former smokers should avoid beta carotene.

Source: Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28

Trials that found no significant effect

Omega-3 oils showed no significant benefit in that trial, or at ten years.

A trial of 25871 people found no significant effect of omega-3 or vitamin D on macular degeneration.

Source: Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial

Vitamin E alone "does not prevent the development or progression" of the disease, one trial found.

Source: Vitamin E supplementation and macular degeneration: randomised controlled trial

A ten-year trial in 39876 women found vitamin E "had no large beneficial or harmful effect."

Source: Vitamin E and age-related macular degeneration in a randomized trial of women

Other ingredients studied

Saffron has been tested in one small trial of mild to moderate disease.

In that trial of 100 people, it "modestly improved visual function."

The average gain was 0.69 letters on the eye chart, which is less than one letter.

Source: Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial

Over the next year with no comparison group, retinal electrical responses improved modestly.

Vision was 1.6 letters worse on average.

The authors thought cataract changes may explain it.

Source: Saffron therapy for the ongoing treatment of age-related macular degeneration

A trial of 106 people tested acetyl-L-carnitine, omega-3 oils and coenzyme Q10 together.

It reported a "Decrease in drusen-covered area of treated eyes" compared with placebo.

Source: Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10

That was one trial of three ingredients together.

It does not show which one mattered.

Medical treatment

Wet disease is treated with injections into the eye that block new vessel growth.

In one trial these "prevented vision loss and improved mean visual acuity."

Source: Ranibizumab for neovascular age-related macular degeneration

If you have wet disease, nothing on this page replaces or delays your injections.

Two injected drugs now treat geographic atrophy.

Across their trials, atrophy grew 11% to 22% more slowly than with sham treatment.

One 12-month result did not reach statistical significance.

The pegcetacoplan trials found "no differences in key secondary visual function endpoints."

New wet disease was more common in treated eyes.

Source: Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY), The Lancet, 2023

Source: Efficacy and safety of avacincaptad pegol in geographic atrophy (GATHER2): 12-month results, The Lancet, 2023

A light treatment has also been tested in intermediate dry disease.

Its trial found a gain of 2.4 letters over the comparison group.

The comparison group also gained 3 letters.

Some of the authors worked for the device maker.

Source: LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration, Retina, 2024

How I think about macular degeneration

What follows is my own view, from many years in natural eye care.

It is not proven by the studies above.

I think of the early stage as a waste problem, where the eye takes in more than it can clear.

I believe sugar damage to proteins plays a large part.

I also believe the liver's handling of fats and the circulation to the eye matter.

So the approaches I teach aim at four things.

Not smoking belongs in any approach.

None of these approaches has been shown in a trial to reverse macular degeneration.

What to ask your eye doctor

Ask which stage you have, in each eye.

Ask for an OCT scan, and keep copies of the reports.

Ask whether a supplement like those in the large trials fits your stage.

Check each eye alone with a grid of straight lines, and report any new waviness at once.

Keep working with your own eye doctor throughout.